Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 89
Appendix A Workshop Agenda PUBLIC ENGAGEMENT AND CLINICAL TRIALS: NEW MODELS AND DISRUPTIVE TECHNOLOGIES June 27-28, 2011 Conduits and Department of Health Evidence and Policy Mount Sinai School of Medicine Goldwurm Auditorium Icahn Medical Institute, 1st Floor 1425 Madison Ave. (at the NE corner of East 98th St.) New York, NY 10029 Background: Rapid advances in biomedical research have drawn attention to the critical need for an effective clinical trial system that can generate the evidence needed to translate discoveries into improved patient care, and illuminate targets for further innovation. There is growing recognition, however, that the U.S. clinical trial enterprise is unable to keep pace with the national demand for actionable research results, and inefficiencies in the clinical trial enterprise limit our ability to realize the clinical benefits of scientific discovery. Many clinical trials never meet their recruitment goals and others are accruing patients far too slowly. In addition, the divide between clinical research and clinical practice is growing wider—physicians working in real world clinical care settings are removed from the clinical trials on which medical evidence and care choices are ideally made. Successfully engaging 89
OCR for page 90
90 PUBLIC ENGAGEMENT AND CLINICAL TRIALS the broader public (including patients and communities) and medical pro- fessionals (community physicians and those practicing in academic medical centers) in the clinical trial enterprise is a significant challenge. In light of these current challenges to clinical trials in the United States, this collaboration between the IOM Forum on Drug Discovery, Develop- ment, and Translation and Mount Sinai School of Medicine seeks to engage stakeholders and experts in an open discussion of current challenges and potential solutions to improving the capacity for efficient conduct of clinical trials in the United States through enhancing public engagement. Meeting Objectives: • efine and discuss the problem of inadequate public engagement in D clinical trials. • dentify the structures and culture of health care systems and deliv- I ery organizations that fail to support or engage with the clinical trial enterprise and suggest potential solutions for how health centers can be engaged to support the clinical trial enterprise. • iscuss how academic medical centers can create successful commu- D nity partnerships to improve public engagement in clinical trials. • ighlight and discuss models/methods, both proven and yet to H be tried, of public engagement. Address the media’s role in public engagement. • escribe novel clinical trial designs (such as adaptive clinical trial D designs) that minimize enrollment needs and address treatment assignment concerns of physicians and their patients. • nvolve stakeholders in a discussion of moving forward to create a com- I prehensive strategy for enhanced public engagement in clinical trials. JUNE 27 SESSION I: FRAMING THE PROBLEM Moderator: Jeffrey Drazen, Co-Chair, Forum on Drug Discovery, Development and Translation, New England Journal of Medicine Session Objectives: • rovide a definition of “engagement,” both public and professional, P in clinical trials. • urvey the current landscape in terms of deficiencies in public and S professional engagement, and discuss consequences of this lack of engagement. • dentify gaps/areas of particular need, desired outcomes of enhanced I engagement, and the challenges facing this progress.
OCR for page 91
91 APPENDIX A 12:00-12:10 PM Welcome Dennis Charney, Dean, Mount Sinai School of Medicine Jeffrey Drazen, Co-Chair, Forum on Drug Discovery, Development and Translation, New England Journal of Medicine 12:10-12:25 PM Shaping an Effective and Efficient Clinical Trial Enterprise: What Are the Challenges? annetine GeliJns anD Deborah asCheim, Mount Sinai School of Medicine 12:25-12:45 PM An Effective Clinical Trial System: A Perspective from the NIH Clinical Center Juan lertora, National Institutes of Health 12:45-1:30 PM Panel Discussion: A Perspective from Industry, Patient Advocates, Payors, and Regulatory Agencies leslie ball, fDa Joan finneGan brooks, Patient-Focused Market Research anGela GeiGer, Alzheimer’s Association riCharD murray, Merck GreG simon, Pfizer bruCe VlaDeCk, Nexera SESSION II: MODELS AND METHODS FOR PUBLIC ENGAGEMENT Moderator: Nancy Sung, Burroughs Wellcome Fund Session Objectives: • hrough case examples, discuss various stakeholder perspectives T and efforts focused on public engagement. In case studies, identify
OCR for page 92
92 PUBLIC ENGAGEMENT AND CLINICAL TRIALS primary audiences, key messages, and success or lack of success in engaging the public. • resent strategies that foster research interest and participation in P diverse populations through innovative community partnerships. 1:35-1:50 PM Recruitment Challenges in Cardiothoracic Surgical Trials robert miChler, Montefiore-Einstein Heart Center 1:50-2:05 PM Diabetes, Clinical Trials, and Innovative Community Partnerships Carol horowitz anD nina biCkell, Mount Sinai School of Medicine 2:05-2:20 PM Clinical Trials in Mental Health wayne GooDman, Mount Sinai School of Medicine 2:20-2:35 PM Recruitment in Breast Cancer Trials, A New Approach: The Love/Avon Army of Women marC hurlbert, Avon Foundation Breast Cancer Crusade 2:35-2:55 PM Panel Discussion kenneth DaVis, The Mount Sinai Medical Center robert miChler, Carol horowitz, nina biCkell, wayne GooDman, marC hurlbert 2:55-3:20 PM COFFEE BREAK
OCR for page 93
93 APPENDIX A SESSION III: TECHNOLOGIES AND NOVEL COMMUNICATION APPROACHES Moderator: Janet Tobias, Mount Sinai School of Medicine Session Objectives: • resent innovative technologies/platforms that hold promise for P achieving higher levels of public awareness (e.g., clinical trial match - ing; increasing adherence; online information efforts). 3:25-3:40 PM 23andMe brian nauGhton, Chief Scientist, 23andMe 3:40-3:55 PM Social Networks and Public Engagement in Clinical Trials bernaDette boDen-albala, Columbia University 3:55-4:15 PM Panel Discussion SESSION IV: MEDIA AND PUBLIC ENGAGEMENT IN CLINICAL TRIALS Moderator: Paul Costello, Stanford School of Medicine Session Objectives: • iscuss the role in public engagement of media, health care informa- D tion portals, and public advocates. 4:20-4:35 PM Survey of the Public Perception and Media Landscape Christina zarCaDoolas, CUNY and Mount Sinai School of Medicine Janet tobias, Mount Sinai School of Medicine 4:35-4:55 PM A Recent Trial of Pediatric Fluid Resuscitation and Novel Methods for Physician Engagement kathryn maitlanD, Imperial College
OCR for page 94
94 PUBLIC ENGAGEMENT AND CLINICAL TRIALS 4:55-5:40 PM Panel Discussion: Public Information and Public Advocacy Joan finneGan brooks, Patient-Focused Market Research PeGGy PeCk, MedPage Today roGer serGel, ABC heather won tesoriero, CBS Christina zarCaDoolas, CUNY and Mount Sinai School of Medicine JUNE 28 SESSION V: NOVEL CLINICAL TRIAL DESIGN Moderator: Michael Krams, Johnson & Johnson Session Objectives: • resent novel clinical trial designs currently in use (e.g., adaptive trial P designs), their strengths and weaknesses, and the desirability and/or feasibility of scaling up the widespread use of such designs. • iscuss the ways in which novel clinical trial designs can enhance D public engagement in clinical research and address treatment assign- ment concerns of physicians and their patients. 8:05-8:20 AM The Promise of Novel Trial Designs miChael PariDes, Mount Sinai School of Medicine 8:20-8:35 AM Trial Designs Addressing Treatment Assignment Concerns louis fiore, VA Boston Healthcare System 8:35-8:55 AM Perspective of the Food and Drug Administration (FDA) bram zuCkerman, Center for Devices and Radiological Health, FDA
OCR for page 95
95 APPENDIX A DouGlas C. throCkmorton, Center for Drug Evaluation and Research, FDA 8:55-9:15 AM Panel Discussion SESSION VI: HEALTH SYSTEM STRUCTURES AND CULTURE Moderator: Harry Greenberg, Stanford University Session Objectives: • resent case studies that include a health system perspective on P public and professional engagement methods and approaches and address broader culture and infrastructure/systemic issues. • ow can health systems develop a culture conducive to conducting H clinical trials, including incentives for the careers of health profession- als, systems approaches to better identify potential enrollees, engage- ment of referring physician community? • or a health care delivery system, what are the suggested messages/ F approaches to enhance public support, understanding, buy-in, and ultimately participation in clinical trials? What organizations at the local level can be leveraged to achieve this? • ow can academic medical centers create effective community part- H nerships to improve public engagement in clinical trials? 9:20-9:35 AM Building a Clinical Trials Culture in Academia eriC rose, Mount Sinai School of Medicine 9:35-9:50 AM Exploring Novel Institutional Models in Cancer GeorGe Demetri, Dana-Farber Cancer Institute and Harvard Medical School 9:50-10:05 AM New Organizational Models in Rheumatoid Arthritis Trials James o’Dell, Rheumatoid Arthritis Investiga- tional Network (RAIN), University of Nebraska 10:05-10:20 AM ResearchMatch.org and Other IT Solutions Paul harris, Vanderbilt University
OCR for page 96
96 PUBLIC ENGAGEMENT AND CLINICAL TRIALS 10:20-10:40 AM Panel Discussion 10:40-11:00 AM COFFEE BREAK 11:00-11:45 AM Building Connections Between Community Physicians and Academic Medicine: The Challenges Panel Moderated by: huGh samPson, Mount Sinai School of Medicine sanforD frieDman, The Mount Sinai Hospital rafat abonour, Indiana University Simon Cancer Center ramon murPhy, Mount Sinai School of Medicine Carol horowitz, Mount Sinai School of Medicine SESSION VII: BUILDING A COMPREHENSIVE STRATEGY Session Objectives: • hat are the most promising methods and messages for public and W professional engagement that you heard during this meeting? What is the likelihood of action? How can they be prioritized? • hat would be the ideal technology to enhance public and profes- W sional engagement? • hat are the most pressing structural and cultural needs for a local W health care system to enhance promotion of public and professional engagement and participation in clinical trials? • hat efforts aimed at physicians, researchers, patients, and the W broader public will facilitate closing the gap between clinical research- ers and clinical practitioners? 11:45 AM-12:05 PM The Changing Politics of Clinical Trial Engagement larry brown, Columbia University
OCR for page 97
97 APPENDIX A 12:05-12:15 PM Building a Comprehensive Strategy: A Summary of the Meeting Jeffrey Drazen, New England Journal of Medicine 12:15-12:30 PM Summary Discussion Jeffrey Drazen, New England Journal of Medicine Juan lertora, National Institutes of Health GreG simon, Pfizer nanCy sunG, Burroughs Wellcome Fund 12:30 PM Adjourn
OCR for page 98